Biognosys Launches Industrialised Discovery Proteomics Service
The standardised, scalable proteomics workflow is now available through Biognosys Group's US laboratories.
Updated on Nov. 19, 2026 in Biotech

Biognosys Group, a fully owned affiliate of Bruker Corporation, has launched Industrialised Discovery, a standardised proteomics service. Early customers at Novalix and Champions Oncology have already used the workflow in US laboratories.
Why it matters
Proteomics has been hard to run routinely at scale because of cost, throughput, turnaround time and reproducibility challenges. Industrialised Discovery aims to make large-scale protein studies more accessible to pharmaceutical, biotechnology and translational research organisations worldwide.
The vendor reports over 10,000 protein identifications from as few as 50,000 HEK-293 cells and turnaround of 100 samples in under 3 weeks or 1,000 samples in under 10 weeks. These figures are company-reported, and independent validation and pricing have not been provided.
The players
Biognosys Group
A proteomics company and fully owned affiliate of Bruker Corporation that develops mass spectrometry data analysis software and services.
Bruker Corporation
A scientific instrumentation company that manufactures the timsTOF mass spectrometers used in the new workflow.
The details
Industrialised Discovery combines sample preparation technologies (iST and iST-S) from PreOmics, timsTOF mass spectrometers from Bruker, and Spectronaut automated with OmicsFlow data analysis software from Biognosys. Quality control is embedded at every stage of the end-to-end workflow.
Timeline
November 19, 2026: Biognosys announces the launch of Industrialised Discovery.
Tech Landscape
Industrialised Discovery builds on the Spectronaut analysis software and timsTOF mass spectrometer platform, packaging them into a standardised offering rather than a new instrument. It extends proteomics from a bespoke laboratory activity toward a repeatable, service-based model.
Research organisations that rely on proteomics could gain access to larger-scale protein studies through standardised turnaround times. Pharmaceutical and translational research teams may find routine proteomics more practical to schedule and budget for.
The takeaway
Standardised service models could make large-scale proteomics practical for a wider range of research teams. Teams evaluating proteomics workflows should compare turnaround, sample requirements and validation data before committing.
Further reading
Explore more Biotech coverage for context on how proteomics services are reshaping drug research.
Source note: This article includes information reported by Scientist Live.



